Delta-Fly Pharma, Inc. (JP:4598)
:4598
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥200.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥2.69B
Enterprise Value¥2.28B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-33.68
Shares Outstanding12,975,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio1.83
Price to Book (P/B)18.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt materially reduces refinancing and interest-rate risk over the next several quarters. For a cash-burning biotech this limits fixed financial obligations, preserving optionality for funding choices and lowering default risk versus peers with higher leverage.
Proprietary Drug DeliveryOwning a proprietary drug delivery platform can create sustainable competitive differentiation in oncology, raising technical barriers and enabling premium positioning or licensing. Over months, this supports durable partnership interest and potential higher value capture if clinical results are favorable.
Diverse Funding PathwaysAbility to secure licensing, milestone-based partnerships, grants and collaborations provides multiple non-sales funding channels. This structural flexibility reduces single-point funding risk and helps sustain development programs while clinical readouts and regulatory milestones are pursued.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates ongoing cash burn and reliance on external financing. Over 2–6 months this raises execution risk, forces frequent capital raises that can dilute shareholders, and constrains the pace of clinical development absent new funding.
Absent Commercial RevenueWith little to no product revenue and net losses deepening in 2025, the company lacks internal cash generation to fund programs. Structurally, this heightens dependency on successful trials and external deals; failure or delays in the pipeline directly threaten sustainability.
Eroding Equity BaseA shrinking equity and asset base signals that past losses have consumed shareholder capital, reducing financial flexibility. Over the medium term this makes future fundraising more dilutive and costly, and limits the firm's ability to absorb setbacks or scale development concurrently.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥200.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.69B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 46 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Feb 13, 2026. The company reported -¥33.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥33.68.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 12,975,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥33.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.802%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.